Literature DB >> 12787631

Coagulation factor VIII: structure and stability.

Wei Wang1, Y John Wang, Drew N Kelner.   

Abstract

Factor VIII (FVIII), a coagulation factor in the blood, is one of the most complex proteins known today. To facilitate the rapid development of a more convenient and safer FVIII product and to improve the quality of life for hemophilia patients, this short article reviews the recent investigations on the structure, activity, and more importantly, stability of FVIII.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12787631     DOI： 10.1016/s0378-5173(03)00227-8

Source DB:  PubMed          Journal:  Int J Pharm        ISSN： 0378-5173            Impact factor:   5.875


  9 in total

1.  Maternal dietary choline deficiency alters angiogenesis in fetal mouse hippocampus.

Authors:  Mihai G Mehedint; Corneliu N Craciunescu; Steven H Zeisel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

2.  Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2016-09-13       Impact factor: 1.627

3.  Paroxysmal atrial fibrillation: changes in factor VIII and von Willebrand factor impose early hypercoagulability.

Authors:  Mariya Negrinova Negreva; Krasimira Prodanova; Katerina Vitlianova; Christiana Madjova
Journal:  Arch Med Sci Atheroscler Dis       Date:  2020-07-11

4.  Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

Authors:  Matthew P Kosloski; Krithika A Shetty; Hironao Wakabayashi; Philip J Fay; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

5.  Influence of peptide ligand surface density and ethylene oxide spacer arm on the capture of porcine parvovirus.

Authors:  Caryn L Heldt; Patrick V Gurgel; Lee-Ann Jaykus; Ruben G Carbonell
Journal:  Biotechnol Prog       Date:  2009 Sep-Oct

6.  Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2014-04-02       Impact factor: 3.534

7.  Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C.

Authors:  Mariasanta Napolitano; Arne Agerlin Olsen; Anne Mette Nøhr; Hermann Eichler
Journal:  J Blood Med       Date:  2021-01-25

Review 8.  Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.

Authors:  Flora Peyvandi; Syna Miri; Isabella Garagiola
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

Review 9.  Application of non-metal nanoparticles, as a novel approach, for improving the stability of blood products: 2011-2021.

Authors:  Tahereh Zadeh Mehrizi; Mehdi Shafiee Ardestani
Journal:  Prog Biomater       Date:  2022-05-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.